These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 37221314)
1. Deprescribing interventions for gabapentinoids in adults: A scoping review. Anderson PA; McLachlan AJ; Abdel Shaheed C; Gnjidic D; Ivers R; Mathieson S Br J Clin Pharmacol; 2023 Sep; 89(9):2677-2690. PubMed ID: 37221314 [TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
3. Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis. Reeve J; Maden M; Hill R; Turk A; Mahtani K; Wong G; Lasserson D; Krska J; Mangin D; Byng R; Wallace E; Ranson E Health Technol Assess; 2022 Jul; 26(32):1-148. PubMed ID: 35894932 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients. Ibiloye EA; Barner JC; Lawson KA; Rascati KL; Evoy KE; Peckham AM Clin Drug Investig; 2021 Mar; 41(3):245-253. PubMed ID: 33580482 [TBL] [Abstract][Full Text] [Related]
13. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Page AT; Clifford RM; Potter K; Schwartz D; Etherton-Beer CD Br J Clin Pharmacol; 2016 Sep; 82(3):583-623. PubMed ID: 27077231 [TBL] [Abstract][Full Text] [Related]
14. Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth. McAnally H; Bonnet U; Kaye AD Pain Ther; 2020 Dec; 9(2):441-452. PubMed ID: 32737803 [TBL] [Abstract][Full Text] [Related]
15. Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. Evoy KE; Covvey JR; Peckham AM; Reveles KR Int J Clin Pharm; 2021 Aug; 43(4):1055-1064. PubMed ID: 33387188 [TBL] [Abstract][Full Text] [Related]
16. Fatalities associated with gabapentinoids in England (2004-2020). Kalk NJ; Chiu CT; Sadoughi R; Baho H; Williams BD; Taylor D; Copeland CS Br J Clin Pharmacol; 2022 Aug; 88(8):3911-3917. PubMed ID: 35435281 [TBL] [Abstract][Full Text] [Related]
17. Pharmacist interventions to deprescribe opioids and benzodiazepines in older adults: A rapid review. Niznik JD; Collins BJ; Armistead LT; Larson CK; Kelley CJ; Hughes TD; Sanders KA; Carlson R; Ferreri SP Res Social Adm Pharm; 2022 Jun; 18(6):2913-2921. PubMed ID: 34281786 [TBL] [Abstract][Full Text] [Related]
18. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Boghossian TA; Rashid FJ; Thompson W; Welch V; Moayyedi P; Rojas-Fernandez C; Pottie K; Farrell B Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011969. PubMed ID: 28301676 [TBL] [Abstract][Full Text] [Related]
19. A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database. Chiappini S; Schifano F CNS Drugs; 2016 Jul; 30(7):647-54. PubMed ID: 27312320 [TBL] [Abstract][Full Text] [Related]
20. The value of deprescribing in older adults with dementia: a narrative review. Sawan MJ; Moga DC; Ma MJ; Ng JC; Johnell K; Gnjidic D Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1367-1382. PubMed ID: 34311630 [No Abstract] [Full Text] [Related] [Next] [New Search]